1-15 of 15
Ira Zackon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Treatment Patterns and Molecular Response (MR) Among Patients with Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) in a Large Community Oncology Setting

Ira Zackon, April Beeks, David Wei, Chuck Wentworth, Jinhong Guo, Courtney McDermott, Kejal Jadhav, Lisa Herms, Andrea Damon, Islam Sadek, Christopher B. Benton
Journal: Blood
Blood (2024) 144 (Supplement 1): 6611.
https://doi.org/10.1182/blood-2024-210681
Published: 2024
Journal Articles

Treatment with Zanubrutinib in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Previously Treated with Another Bruton Tyrosine Kinase Inhibitor in a US Community Oncology Setting

David Andorsky, Brittani Wayne, Chuck Wentworth, Yunfei Wang, Scott Goldfarb, Keri Yang, Erlene Kuizon Seymour, Mark Balk, Gregory A. Maglinte, Ira Zackon
Journal: Blood
Blood (2024) 144 (Supplement 1): 7763.
https://doi.org/10.1182/blood-2024-205940
Published: 2024
Journal Articles

The Evolution of Treatment Patterns for Chronic Lymphocytic Leukemia (CLL): Trends in the US Community Oncology Setting from 2015 to 2024

Zhaohui Su, Lisa Herms, Jessica Paulus, Nicholas Robert, Ira Zackon
Journal: Blood
Blood (2024) 144 (Supplement 1): 6792.
https://doi.org/10.1182/blood-2024-210905
Published: 2024
Journal Articles

Clinical Outcomes and Adverse Events Among Patients with Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL) Initiating First-Line (1L) Ibrutinib: Analysis of Subgroups Receiving Subsequent Second Generation (2G) Bruton Tyrosine Kinase Inhibitors, Non-Bruton Tyrosine Kinase Inhibitor Therapy, or Ibrutinib Retreatment in the US Community Oncology Setting

John M. Burke, Ira Zackon, Brittani Wayne, Yunfei Wang, John Murphy, Jennifer Prescott, Shravanthi Gandra, Siyang Leng, Enrico De Nigris
Journal: Blood
Blood (2024) 144 (Supplement 1): 7811.
https://doi.org/10.1182/blood-2024-203667
Published: 2024
Journal Articles

Using NLP to Identify CAR T-Cell Therapy Recipients from Oncology Progress Notes

Avi Raju, Lisa Herms, Zhaohui Su, Ira Zackon, Jessica Paulus
Journal: Blood
Blood (2024) 144 (Supplement 1): 7486.
https://doi.org/10.1182/blood-2024-205446
Published: 2024
Journal Articles

Demographics and Mortality of Patients Diagnosed with Multiple Myeloma Treated in the US Community Oncology Setting from 2018 to 2023: Assessing Trends in the Pre-, Peri- and Post-Pandemic Eras

Lisa Herms, Zhaohui Su, Jessica Paulus, Ira Zackon
Journal: Blood
Blood (2024) 144 (Supplement 1): 6939.
https://doi.org/10.1182/blood-2024-208788
Published: 2024
Journal Articles

Real-World Baseline Characteristics and Preliminary Outcomes in Patients with Myelofibrosis Treated with Momelotinib in the US Community Oncology Practice Setting

Luke Fletcher, Nicole Niehoff, Sneha Sura, Tom Liu, Karen Todoroff, William Zhang, Ira Zackon
Journal: Blood
Blood (2024) 144 (Supplement 1): 2430.
https://doi.org/10.1182/blood-2024-199834
Published: 2024
Journal Articles

Real-World Utilization of Bispecific Antibodies for Treatment of Relapsed/Refractory Multiple Myeloma in the US Community Oncology Setting

Lisa Herms, Zhaohui Su, Jessica Paulus, Ira Zackon
Journal: Blood
Blood (2024) 144 (Supplement 1): 2410.
https://doi.org/10.1182/blood-2024-208825
Published: 2024
Journal Articles

Trends in Real-World Characteristics and Outcomes of Patients with Diffuse Large B-Cell Lymphoma Treated in the US Community Oncology Setting Pre- and Post-CAR-T Approvals

Lisa Herms, Zhaohui Su, Jessica Paulus, Ira Zackon
Journal: Blood
Blood (2024) 144 (Supplement 1): 3094.
https://doi.org/10.1182/blood-2024-208973
Published: 2024
Journal Articles

Recent Patterns of Care with BTK Inhibitors and Distribution of Social Determinants of Health Among Patients with CLL/SLL in the US Community Setting

David J Andorsky, Ira Zackon, Thomas W Wilson, Kathleen M Aguilar, Chuck Wentworth, Yunfei Wang, Scott Goldfarb, Keri Yang, Erlene Kuizon Seymour, Mark Balk, Gregory A Maglinte
Journal: Blood
Blood (2023) 142 (Supplement 1): 2413.
https://doi.org/10.1182/blood-2023-172880
Published: 2023
Journal Articles

Non-Relapse Mortality and Quality of Life with Shared Care after Allogeneic Hematopoietic Cell Transplantation: A Randomized Control Trial

Gregory A. Abel, Haesook T Kim, Ira Zackon, Edwin P. Alyea, III, Alexandra Bailey, John P. Winters, Kenneth R. Meehan, John L Reagan, Jeanna Walsh, Meredith Faggen, Sarah Sinclair, Amy Joyce, Sara Close, Amy Emmert, Isabella Kallassy, John Koreth, Joseph H. Antin, Corey Cutler, Vincent T Ho, Robert J Soiffer
Journal: Blood
Blood (2022) 140 (Supplement 1): 2135–2136.
https://doi.org/10.1182/blood-2022-166996
Published: 2022
Journal Articles

Treatment Patterns and Overall Survival (OS) Among Patients with Myelodysplastic Syndromes (MDS) Treated in the US Community Oncology Setting: A Real-World Retrospective Observational Study

Roger M. Lyons, Wei-Han Cheng, Laura Moore-Schiltz, Ping Shi, Anders Svensson, Cat N. Bui, Jessica E. Hutti, Ann Marie McNeill, Elizabeth S. Mearns, Archibong Yellow-Duke, Ira Zackon
Journal: Blood
Blood (2022) 140 (Supplement 1): 6938–6939.
https://doi.org/10.1182/blood-2022-163098
Published: 2022
Journal Articles

Characteristics, Blood Counts, Treatments, and Clinical Outcomes of 5871 Patients with Polycythemia Vera Treated in US Community Practices

Roger M. Lyons, Kathleen M. Aguilar, Lavanya Sudharshan, Divea Venkatasetty, Juliet Ndukum, Ira Zackon, Jingbo Yu
Journal: Blood
Blood (2022) 140 (Supplement 1): 13310–13311.
https://doi.org/10.1182/blood-2022-163416
Published: 2022
Journal Articles

Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma

Jacob P. Laubach, MD, Noopur Raje, MD, Andrew J. Yee, MD, Philippe Armand, MD PhD, Robert L. Schlossman, MD, Jacalyn Rosenblatt, MD, Michael G. Martin, MD, Craig Reynolds, MD, Kenneth H. Shain, MD PhD, Ira Zackon, MD, Laura V. Stampleman, MD, Emily Lai, BS, Aaron M. Caola, BS, Joseph M. Cappuccio, BS, Bradley Rivotto, BS, Kaitlen Reyes, DNP, Alexandra Savell, BS, Patrick Henrick, BS, Tillman Pearce, MD, Damian Handisides, Stew Kroll, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Irene M. Ghobrial, MD
Journal: Blood
Blood (2016) 128 (22): 2122.
https://doi.org/10.1182/blood.V128.22.2122.2122
Published: 2016
Journal Articles

A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma

Jacob P. Laubach, MD, Noopur S. Raje, MD, Andrew J. Yee, MD, Philippe Armand, MD PhD, Robert L. Schlossman, MD, Jacalyn Rosenblatt, MD, Jeffrey Matous, MD, Jacquelyn Hedlund, MD, Michael G Martin, MD, Craig Reynolds, MD, Kenneth H. Shain, MD PhD, Ira Zackon, MD, Laura V. Stampleman, MD, Erica N Boswell, BS, Stacey Chuma, BSN, Rebecca Liguori, MS, Stephanie Mar, Damian Handisides, Stew Kroll, Kenneth C. Anderson, MD, Paul G. Richardson, Irene M. Ghobrial, MD
Journal: Blood
Blood (2014) 124 (21): 2142.
https://doi.org/10.1182/blood.V124.21.2142.2142
Published: 2014